Professional Documents
Culture Documents
DR.SHERIF SAAD
(M.B.B.Ch., M.Sc., M.D.)
Consultant of Psychiatry
International member of American Psychiatric Association (APA)
International member of European Psychiatric Association (EPA)
POPULATION AGEING
- Confusion
- Poor judgment
-D = Delirium
-N = Nutritional Disorders
-I = Infectious Disorders
-A = Alcohol, Arteriosclerosis
PRIMARY SYMPTOMS
- ATTENTION
- MEMORY
- POSTROLANDIC (“COGNITION”)
- EXECUTIVE (FRONTAL/SUBCORTICAL)
- INSIGHT
PRIMARY SYMPTOMS
- MEMORY: forgetfulness
Brain
Cognitive Decline
“Brain”AD
Aging
MCI Mild
Moderate
Clinical AD Moderately
Severe
Severe
- Disruption of cerebral
neuronal circuit
- Loss of neurons,
- Neuro fibrillary tangles,
- Senile plaques and
- Amyloid angiopathy are
seen, especially within
the frontal, temporal and
parietal cortex,
hippocampi, substantia
innominata and locus
caeruleus.
AD and the Brain
Plaques and Tangles: The Hallmarks of AD
The brains of people with AD have an abundance of two abnormal
structures:
- beta-amyloid plaques, which are dense deposits of protein & cellular
material that accumulate outside and around nerve cells
- neurofibrillary tangles, which are twisted fibers that build up inside the
nerve cell
- Some people may need to stay in the hospital for a short time.
- Stopping or changing medications that make confusion worse may improve brain
function.
- There is growing evidence that some kinds of mental exercises can help dementia.
Treatment of Alzheimer’s Disease
Prevention
- Antioxidants (Ginkgo biloba)
Slowing Progression - Anti-inflammatory drugs (ADAPT)
- Anti-oxidants (vitamin E) - amyloid antagonists
- Anti-inflammatory drugs - secretase inhibitors
- Hormones (estrogen) - anti-aggregation compounds
- Neuroprotective agents (NGF) - amyloid vaccines
- Reducing vascular risk - Anti-neurofibrillar drugs
- statins, homocysteine reduction - Genetic engineering
TREATMENT OUTCOMES IN ALZHEIMER’S DISEASE
Cure
Maintenance
Functional ability
of function
Slowing of disease
progression
Treatment
Symptomatic
benefit
Natural Progression
At present, there is no cure for AD, but treatment has been shown to
provide significant benefits compared with no treatment
SYMPTOMATIC EFFECTS VERSUS SLOWING DISEASE
PROGRESSION
Mild
Impairment
Placebo
Symptomatic
Disease modifying
Severe
Baseline End
Treatment Period (Ferris, 8/03)
Behavioral and Psychological Symptoms
of Dementia (BPSD)
Behavioral and Psychological Symptoms
of Dementia (BPSD)
- A heterogeneous range of psychological reactions, psychiatric symptoms,
and behaviors occurring in people with dementia of any etiology.
- Any verbal, vocal, or motor activities not judged to be clearly related to the
needs of the individual or the requirements of the situation
- Caregiver stress
- Increased ER visits
- Placement in LTC
100
Frequency (% of Patients)
Agitation
80
Diurnal
60 rhythm
Depression Irritability
Wandering
40 Social Aggression
withdrawal
Anxiety Mood
change
20 Paranoia
Hallucinations
- Of 12 behaviours examined, 4 correlated with tissue loss: apathy, disinhibition, eating disorders and aberrant
motor behaviour. Increasing severity across these four behaviours was associated with tissue loss in the ventral portion
of the right anterior cingulate cortex (vACC) and adjacent ventromedial superior frontal gyrus (vmSFG), the right ventro-
medial prefrontal cortex (VMPC) more posteriorly, the right lateral middle frontal gyrus, the right caudate head, the right
orbitofrontal cortex and the right anterior insula.
- In addition, apathy was independently associated with tissue loss in the right ventromedial superior frontal gyrus
(vmSFG), disinhibition with tissue loss in the right subgenual cingulate gyrus in the VMPC, and aberrant motor
behaviour with tissue loss in the right dorsal ACC and left premotor cortex.
- These data strongly support the involvement of the right hemisphere in mediating social and emotional behaviour
and highlight the importance of distinct regions on the medial wall of the right frontal lobe in regulating different
behaviours.
- Furthermore, the findings underscore the utility of studying patients with dementia for understanding the neuroanatomi-
cal basis of social and emotional functions.
Neuroanatomical correlates of behavioural
disorders in dementia
Brain (2005), 128, 2612–2625
vACC = ventral portion of the right anterior cingulate cortex, vmSFG = ventromedial superior frontal gyrus,
SGC = subgenual cingulate gyrus,
Evaluation
FAMILY SUPPORT IS
VERY HELPFUL
Behavioral interventions
WARNING:
INCREASED MORTALITY FOR ELDERLY
PATIENTS WITH DEMENTIA RELATED PSY-
CHOSES.
Elderly patients with dementia related psy-
choses are at increased risk for death com-
pared to placebo.
These drug is not approved for the treat-
ment of dementia related psychoses.
FDA Blackbox on antipsychotics
- Meta-analysis of 17 double blind RCT’s in elderly dementia patients, April
2005.
- Sedation
- Gait disturbances
- Falls
Conclusions:
Serious events, as indicated by a hospital admission or death, are frequent following the
short term use of antipsychotic drugs in older adults with dementia.
Antipsychotic drugs should be used with caution even when short-term therapy is being pre-
scribed. Arch Intern Med. 2008;168(10):1090-1096
CATIE-AD Trial
Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's
Disease (CATIE-AD) investigators
- 421 AD patients with psychosis and aggression where randomly assigned to olanzapine,
quetiapine, risperidone, or placebo of “watchful waiting” over 9 months
- No statistical differences between groups, although placebo most often superior in
net health benefit analysis
- Olanzapine group – more impaired on ADL testing- ???sedation, gait disturbance
- Placebo group – best ADL score, lower dependence score, lower total health care costs -
$50-100
- Several methodological drawbacks:
- Subjects were outpatients, less impaired then some BPSD trials
- High dropout rate compared to other RCTs (likely a design feature)
- No washout period
- Dosage likely too low for quetiapine (mean 56.5mg/day)
- Authors concluded adverse events offset advantages in efficacy
Clinical Antipsychotic Trial of Intervention Effectiveness – Alzheimer’s Disease. Rosenheck, Cost-benefit analysis…., Arch Gen. Psychiatry 2007; 64(11):1259-1268.
Antipsychotics in LTC
- Recommendations
- Haloperidol was useful in reducing aggression, but was associated
with adverse effects
- No evidence to support the routine use of this drug for other mani-
festations of agitation in dementia
- Haloperidol should not be used routinely to treat patients with agitat-
ed dementia
THE AMERICAN PSYCHIATRIC ASSOCIATION
PRACTICE GUIDELINE ON THE USE OF
Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia
May 01, 2016
Before treatment with an antipsychotic, the potential risks and benefits should be assessed by the physician and discussed with the
patient and the patient’s surrogate decision maker, with input from the family.
Treatment should be initiated at a low dose and eased up to the minimum effective dose.
If the patient experiences significant side effects, the risks and benefits should be reviewed to determine if the antipsychotic should
be discontinued.
If there is no significant response after a 4-week time period, the medication should be tapered and withdrawn.
In patients who show adequate response to the medication, an attempt to taper and withdraw the antipsychotic should be made
within four months of starting.
In patients whose antipsychotic medications are being tapered, symptoms should be assessed at least every month during tapering
and for at least four months after the medication is discontinued.
A long-acting injectable antipsychotic should not be used unless it is administered for a co-occurring chronic psychotic disorder.
If non-emergency antipsychotic medication treatment is to be used, haloperidol should not be used first.
Recommendations
- Look for etiology of symptoms
- Identify target signs and symptoms, and set a limited time frame (many patients improve without treatment
over 2-4 weeks)
- Well tolerated
- Suggests agitation and psychosis in younger and older populations have different neu-
rochemistry
Trazodone for agitation in dementia
(2004 Cochrane review)
www.cochrane.org/reviews/en/ab004990.html
Valproate preparations for BPSD
(2004 Cochrane review)
- Adverse reactions
- Sedation occurred more frequently than in controls
- Urinary tract infection was more than in controls
- Tariot et al. (1998) completed a nursing home study where 72% of patients
improved versus only 21% placebo
- The Bad News: Concerns about tolerability in elderly, drug-drug interactions, and ad-
verse events unfortunately limit its use
Benzodiazepines
- Several studies support efficacy
- Initial studies focused on cognition, yet there is increasing evidence of a possible behav-
ioral benefit as well
- Several post-hoc analyses of studies with galantamine and donepezil suggest benefi-
cial effects on psychosis, agitation, mood, apathy, and aberrant motor behaviors
- Memantine also appears to delay emergence of agitation and reduce caregiver distress
(Cummings et al 2006)
- SSRI
- Antiandrogen
- Progesterone 5 mg po daily (10 mg IM weekly)
- Leuprolide 5-10 mg IM monthly
Parkinsonian motor disturbances & medications
- Dementia with Lewy bodies (DLB), Parkinson disease (PD) and up to 50% of Alzheimer
disease (AD)
Zhong K, Tariot PN, Mintzer J, et al. Quetiapine for the treatment of agitation in elderly institutionalized patients
with dementia: a randomized, double-blind trial. Presented at the American College of Neuropsychopharmacolo-
gy Annual Meeting; December 12–16, 2004; San Juan, Puerto Rico.
Manic-like syndromes
- Symptoms : pressured speech, disinhibition, elevated mood, intrusiveness, hyperactivi-
ty, reduced sleep